Alps Group Inc(ALPS)

Biotechnology · Kuala Lumpur, WP

$0.38-0.02 (-5.00%)

Delayed quote: Oct 6, 2026, 9:35 AM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T13:35:27.341Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:35:27.341Z.

Quote observation: 2026-10-06T13:35:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 63,232,125
Total debt · period ending 2026-03-31: N/A
Cash · period ending 2026-03-31: N/A
TTM revenue · period ending 2025-09-30: N/A

FMP input reference: 473da95602fdb42a5f780e5c02853506da999e38a33e04168dea7648cb5c925f

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ALPS EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

ALPS Competitors' EV/Sales Ratio

ALPS

Alps Group Inc

Current

Market Cap

$63.23M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs ALPS

Market Cap

$64.31M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GOSS

Gossamer Bio, Inc.

vs ALPS

Market Cap

$65.51M

EV/Sales Ratio

1.19x

TTM Avg

9.45x

3Y Avg

7.55x

5Y Avg

7.55x

CING

Cingulate Inc.

vs ALPS

Market Cap

$64.11M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRS

Kalaris Therapeutics Inc

vs ALPS

Market Cap

$63.30M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INCR

InterCure Ltd.

vs ALPS

Market Cap

$62.78M

EV/Sales Ratio

1.32x

TTM Avg

1.24x

3Y Avg

1.42x

5Y Avg

1.83x

ACET

Adicet Bio, Inc.

vs ALPS

Market Cap

$60.44M

EV/Sales Ratio

N/A

TTM Avg

8.16x

3Y Avg

93.50x

5Y Avg

96.95x

CSBR

Champions Oncology, Inc.

vs ALPS

Market Cap

$68.91M

EV/Sales Ratio

1.24x

TTM Avg

1.43x

3Y Avg

1.60x

5Y Avg

1.76x

FBIO

Fortress Biotech, Inc.

vs ALPS

Market Cap

$70.09M

EV/Sales Ratio

N/A

TTM Avg

1.19x

3Y Avg

0.71x

5Y Avg

0.83x

INKT

MiNK Therapeutics, Inc.

vs ALPS

Market Cap

$60.33M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Alps Group Inc (ALPS)	$63.23M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$64.31M	N/A	N/A	N/A	N/A
Gossamer Bio, Inc. (GOSS)vs ›	$65.51M	1.19x	9.45x	7.55x	7.55x
Cingulate Inc. (CING)vs ›	$64.11M	N/A	N/A	N/A	N/A
Kalaris Therapeutics Inc (KLRS)vs ›	$63.30M	N/A	N/A	N/A	N/A
InterCure Ltd. (INCR)vs ›	$62.78M	1.32x	1.24x	1.42x	1.83x
Adicet Bio, Inc. (ACET)vs ›	$60.44M	N/A	8.16x	93.50x	96.95x
Champions Oncology, Inc. (CSBR)vs ›	$68.91M	1.24x	1.43x	1.60x	1.76x
Fortress Biotech, Inc. (FBIO)vs ›	$70.09M	N/A	1.19x	0.71x	0.83x
MiNK Therapeutics, Inc. (INKT)vs ›	$60.33M	N/A	N/A	N/A	N/A

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics